Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dexcom Inc (DXCM)

Dexcom Inc (DXCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What Are Wall Street Analysts' Target Price for DexCom Stock?

With a market cap of $26.6 billion, DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health management in the United States and internationally. It offers products such as Dexcom G6, Dexcom G7, Dexcom ONE, and Stelo, serving patients, caregivers, and clinicians worldwide.

Shares of the medical device company have underperformed the broader market over the past 52 weeks. DXCM stock has declined 22.8% over this time frame, while the broader S&P 500 Index ($SPX) has gained 14.4%. However, the stock has risen 2.7% on a YTD basis,...

Fundamentals

See More
  • Market Capitalization, $K 26,583,492
  • Shares Outstanding, K 390,016
  • Annual Sales, $ 4,033 M
  • Annual Income, $ 576,200 K
  • EBIT $ 778 M
  • EBITDA $ 995 M
  • 60-Month Beta 1.49
  • Price/Sales 6.15
  • Price/Cash Flow 31.22
  • Price/Book 10.04

Options Overview Details

View History
  • Implied Volatility 58.40% (-1.14%)
  • Historical Volatility 26.53%
  • IV Percentile 82%
  • IV Rank 61.51%
  • IV High 77.57% on 10/30/25
  • IV Low 27.78% on 08/05/25
  • Expected Move (DTE 2) 5.80 (8.51%)
  • Put/Call Vol Ratio 4.39
  • Today's Volume 1,605
  • Volume Avg (30-Day) 4,066
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 108,045
  • Open Int (30-Day) 128,092
  • Expected Range 62.35 to 73.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.65
  • Number of Estimates 12
  • High Estimate 0.69
  • Low Estimate 0.59
  • Prior Year 0.45
  • Growth Rate Est. (year over year) +44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.92 +3.38%
on 01/12/26
75.97 -10.30%
on 01/22/26
+0.75 (+1.11%)
since 01/09/26
3-Month
57.20 +19.14%
on 11/17/25
75.97 -10.30%
on 01/22/26
+10.02 (+17.24%)
since 11/11/25
52-Week
54.11 +25.95%
on 11/07/25
93.25 -26.92%
on 02/18/25
-18.23 (-21.10%)
since 02/11/25

Most Recent Stories

More News
What Are Wall Street Analysts' Target Price for DexCom Stock?

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

XLV : 156.25 (+0.59%)
$SPX : 6,941.47 (unch)
DXCM : 68.15 (-0.01%)
Earnings To Watch: DexCom (DXCM) Reports Q4 Results Tomorrow

Earnings To Watch: DexCom (DXCM) Reports Q4 Results Tomorrow

DXCM : 68.15 (-0.01%)
1 High-Flying Stock with Impressive Fundamentals and 2 We Ignore

1 High-Flying Stock with Impressive Fundamentals and 2 We Ignore

FORM : 96.07 (+2.97%)
NOVT : 141.83 (-2.22%)
DXCM : 68.15 (-0.01%)
1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds

1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds

DG : 147.16 (+0.62%)
KLIC : 74.87 (+0.04%)
DXCM : 68.15 (-0.01%)
Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management

Enhanced Smart Food Logging experience now provides nutritional breakdown of meals Advanced AI-enabled features will deliver easy meal tracking to transform...

DXCM : 68.15 (-0.01%)
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

DXCM : 68.15 (-0.01%)
3 Profitable Stocks for Long-Term Investors

3 Profitable Stocks for Long-Term Investors

RBC : 550.53 (+0.55%)
NNI : 130.63 (-1.39%)
DXCM : 68.15 (-0.01%)
Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will...

DXCM : 68.15 (-0.01%)
INVESTOR NOTICE: Kaskela Law Firm Announces Stockholder Investigation of DexCom, Inc. (NASDAQ: DXCM) and Encourages Long-Term Investors to Contact the Firm

PHILADELPHIA , Jan. 27, 2026 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning DexCom, Inc. (NASDAQ: DXCM) ("Dexcom")...

DXCM : 68.15 (-0.01%)
2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore

2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore

GWRE : 130.41 (-2.12%)
SWK : 90.53 (-1.34%)
DXCM : 68.15 (-0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of...

See More

Key Turning Points

3rd Resistance Point 70.30
2nd Resistance Point 69.42
1st Resistance Point 68.79
Last Price 68.15
1st Support Level 67.28
2nd Support Level 66.40
3rd Support Level 65.77

See More

52-Week High 93.25
Fibonacci 61.8% 78.30
Fibonacci 50% 73.68
Fibonacci 38.2% 69.06
Last Price 68.15
52-Week Low 54.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar